Mesotherapy Lipolytic Solution/PPC Solution Jiangsu Tiera Biotechnology Co., Ltd , https://www.tierabio.com
Recently, a study of cancer patients in the United States who were treated between the 1970s and 1999 showed that despite years of improved survival, the quality of life of survivors remained low.
About 70% of child cancer survivors receive treatment side effects, including secondary cancer. As survival rates increase, the number of child cancer survivors worldwide is increasing.
As an emerging drug field, nanomedicine will bring higher quality of life to children with cancer with lower side effects.
What is nanomedicine?
Nanomedicine is in fact a form of application of nanomaterials or nanoparticles in medicine. Nanoparticles can transport drugs to lesions that are not accessible to common drugs. Nanoparticles for drug delivery are typically in the range of 20 to 100 nm, and nanomedicines can be designed as needed.
This targeted approach means that drugs can be concentrated in specific tumor areas in a predetermined path to maximize damage to the tumor while minimizing collateral damage to surrounding healthy tissue, thereby reducing side effects. Therefore, the nano drug has the characteristics of small particle size, large specific surface area, high activity, etc., and can reduce the dose under the premise of ensuring the efficacy of the drug, and can even be made into a sustained release dosage form, changing the half life of the drug in the body and prolonging the action time. 
The first cancer nano drug approved by the FDA is Doxil. Since 1995, the drug has been used to treat cancer in adults, including ovarian cancer, multiple myeloma, and Karac's sarcoma (a rare cancer common in immunodeficient patients such as AIDS).
Currently, there are already some nanomedicine therapies for adult cancer treatment that are undergoing clinical trials or are already on the market, but only a few have been approved for childhood cancer.
Nanoparticles vary in shape and size, and researchers need to match the right nanoparticles to the drugs they deliver and specific tumors.
A series of nanoparticle structures are currently being designed. An interesting example is a structure similar to DNA folding, which seems to fool the eyes of the immune system, and is not treated as a foreign object, thus avoiding the body's immune system directly reaching the tumor tissue, reducing the drug's side effect.
Among the listed drug research and development companies, there are many top ten pharmaceutical companies in the Fortune 500 (Pfizer, Johnson & Johnson, Merck, Novartis, Roche, GSK, AstraZeneca, Aibowei), and Japanese multinational pharmaceutical companies (Takeda Pharmaceutical, the first three , Astellas), biopharmaceutical giants (Amgen, Gilead, Xaar Gene, Genzan), as well as pharmaceutical companies specializing in nano-agent development, such as Taiwanese Microlipid Co., Ltd., and generic giants ( Teva) and so on.
According to the ClinicalTrials database and the information on the Chinese drug clinical trial registration and information disclosure platform, there are currently nearly 150 nano-dosage drugs under research.
In addition to companies that have a place in the field of nanocarrier drugs, domestic companies entering this field include Xi'an Libang Pharmaceutical Co., Ltd., Wuhan Liyuanheng Pharmaceutical Technology Co., Ltd., Guangzhou Yipinhong Pharmaceutical Co., Ltd., Jiangsu Hengrui Pharmaceutical Co., Ltd. Wuxi Langci Biotechnology Co., Ltd., Nanjing Cisco Pharmaceutical Co., Ltd. / Nanjing Kanghai Pharmaceutical Development Co., Ltd., Shanghai Yizhong Biotechnology Co., Ltd., Shanghai Tianhui Chemical Pharmaceutical Co., Ltd., Sinopharm Yixin Pharmaceutical Co., Ltd., Beijing Tide Pharmaceutical Co., Ltd. Ltd. and Beijing Baiao Pharmaceutical Co., Ltd., etc.
With the development of gene therapy and other fields, the drugs carried by nanomedicine are no longer limited to traditional chemotherapeutic drugs, in molecular targeted agents, antisense nucleotides, small interfering RNA (siRNA), messenger RNA and DNA oligonucleosides. New anticancer drugs such as acid inhibitors have also shown great potential, greatly improving the safety of gene therapy and improving the effectiveness of immunotherapy.
Although many tumor-treating nano-drugs are in the clinical trial stage, there is still a long way to go before it really matures. To achieve clinical application, nano-medicine needs to solve these major challenges at least: (1) controllable and renewable Research on nanoparticle synthesis methods; (2) establishment of a complete clinical evaluation and monitoring system; (3) implementation of good production management practices (GMP), the transition from basic research to clinical products, and subsequent commercial production.
Nanocarrier drugs or new weapons to fight cancer
[ China Pharmaceutical Network Technology News ] The first cancer nano drug approved by the FDA is Doxil. A series of nanoparticle structures are currently being designed. An interesting example is a structure similar to DNA folding, which seems to fool the eyes of the immune system, and is not treated as a foreign object, thus avoiding the body's immune system directly reaching the tumor tissue, reducing the drug's side effect.
(Nano's major development history in the field of cancer)